Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy
Clinical Cancer Research, 12/08/08

Burstein HJ et al. – Bevacizumab and vinorelbine are well tolerated and effective as treatment for refractory breast cancer. Plasma vascular endothelial growth factor therapy (VEGF) warrants further evaluation as a prognostic marker for treatment outcome in advanced breast cancer pts receiving anti-VEGF therapy.

Methods

Study of the efficacy and safety of the humanized monoclonal anti-VEGF antibody, bevacizumab, and vinorelbine as treatment for refractory breast cancer
Investigation of the role of plasma VEGF as a predictor of treatment outcome
Eligibility: 1-2 prior chemotherapy regimens for metastatic breast cancer or recurrence within 12 mo of adjuvant therapy with measurable disease and adequate end-organ function
Administration of bevacizumab 10 mg/kg every 2 wks, and vinorelbine each week, until tumor progression or prohibitive toxicity
Measurement of plasma VEGF at baseline

Results

Of 56 women treated on protocol, 34% response rate
Median time to progression: 5.5 mo
Activity regardless of tumor hormone receptor status or type/extent of prior chemotherapy
Side effects: uncomplicated neutropenia, hypertension, nasal congestion/epistaxis, neuropathy
Post-surgical impaired wound healing in 3 pts
Rare thrombosis or clinically significant proteinuria
Lower levels baseline VEGF associated with longer time to progression